Preclinical and Clinical Characterization of Fibroblast-derived Neuregulin-1 on Trastuzumab and Pertuzumab Activity in HER2-positive Breast Cancer.
Cristina GuardiaGiampaolo BianchiniOriol Arpí-LLuciàSilvia MenendezDavid CasadevallBarbara GalbardiMatteo DugoSonia ServitjaJuan Carlos MonteroLuis Soria-JiménezMohammadA SabbaghiRaul PeñaJuan Madoz-GúrpideBelen LloverasAna LluchPilar ErolesJoaquin ArribasAtanasio PandiellaLuca GianniFederico RojoAna RoviraJoan AlbanellPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
CAF-derived NRG1 mediates trastuzumab resistance through HER3/AKT, which might be reverted by pertuzumab. In patients with HER2-positive breast cancer, high expression of NRG1 was associated to poor response to trastuzumab, but not in combination with pertuzumab.